Tech Company Financing Transactions
NextRNA Therapeutics Funding Round
NextRNA Therapeutics, operating out of Cambridge, secured $56 million from Cobro Ventures, Lightchain and Evans Capital Management.
Transaction Overview
Company Name
Announced On
3/26/2022
Transaction Type
Venture Equity
Amount
$56,000,000
Round
Undisclosed
Investors
Cobro Ventures (Lead Investor)
Lightchain (Lead Investor)
Proceeds Purpose
Proceeds will be used by the company to augment its target and drug discovery engine, expand its pipeline, and advance lead programs.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
650 E Kendall St 2nd Fl
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Historically, RNA has been thought of as a messenger whose role is to translate information from DNA into proteins. However, the vast majority of our DNA is copied into RNAs that do not make proteins. These RNA molecules, called "non-coding RNAs" have now been shown to have an essential role in our cells by interacting with and modulating the activities of proteins that participate in critical cellular events.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Marc Cohen
Co-Founder
Julia Novina
Co-Founder
Dominique Verhelle
Browse more venture capital transactions:
Prev: 3/26/2022: Disco.co venture capital transaction
Next: 3/26/2022: Onego Bio venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs